166 related articles for article (PubMed ID: 20001802)
1. Roles of LPA in ovarian cancer development and progression.
Pua TL; Wang FQ; Fishman DA
Future Oncol; 2009 Dec; 5(10):1659-73. PubMed ID: 20001802
[TBL] [Abstract][Full Text] [Related]
2. Lysophosphatidic Acid Stimulates Ovarian Cancer Cell Migration via a Ras-MEK Kinase 1 Pathway.
Bian D; Su S; Mahanivong C; Cheng RK; Han Q; Pan ZK; Sun P; Huang S
Cancer Res; 2004 Jun; 64(12):4209-17. PubMed ID: 15205333
[TBL] [Abstract][Full Text] [Related]
3. The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer.
Tanyi JL; Morris AJ; Wolf JK; Fang X; Hasegawa Y; Lapushin R; Auersperg N; Sigal YJ; Newman RA; Felix EA; Atkinson EN; Mills GB
Cancer Res; 2003 Mar; 63(5):1073-82. PubMed ID: 12615725
[TBL] [Abstract][Full Text] [Related]
4. Lysophosphatidic acid signaling in ovarian cancer.
Jesionowska A; Cecerska-Heryc E; Matoszka N; Dolegowska B
J Recept Signal Transduct Res; 2015; 35(6):578-84. PubMed ID: 26393967
[TBL] [Abstract][Full Text] [Related]
5. Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells.
Ren J; Xiao YJ; Singh LS; Zhao X; Zhao Z; Feng L; Rose TM; Prestwich GD; Xu Y
Cancer Res; 2006 Mar; 66(6):3006-14. PubMed ID: 16540649
[TBL] [Abstract][Full Text] [Related]
6. Up-regulation of interleukin-6 in human ovarian cancer cell via a Gi/PI3K-Akt/NF-kappaB pathway by lysophosphatidic acid, an ovarian cancer-activating factor.
Chou CH; Wei LH; Kuo ML; Huang YJ; Lai KP; Chen CA; Hsieh CY
Carcinogenesis; 2005 Jan; 26(1):45-52. PubMed ID: 15471896
[TBL] [Abstract][Full Text] [Related]
7. Endogenous RGS proteins attenuate Galpha(i)-mediated lysophosphatidic acid signaling pathways in ovarian cancer cells.
Hurst JH; Henkel PA; Brown AL; Hooks SB
Cell Signal; 2008 Feb; 20(2):381-9. PubMed ID: 18083345
[TBL] [Abstract][Full Text] [Related]
8. Lysophosphatidic acid induction of urokinase plasminogen activator secretion requires activation of the p38MAPK pathway.
Estrella VC; Eder AM; Liu S; Pustilnik TB; Tabassam FH; Claret FX; Gallick GE; Mills GB; Wiener JR
Int J Oncol; 2007 Aug; 31(2):441-9. PubMed ID: 17611702
[TBL] [Abstract][Full Text] [Related]
9. Lysophosphatidic acid receptors in cancer pathobiology.
Tsujiuchi T; Araki M; Hirane M; Dong Y; Fukushima N
Histol Histopathol; 2014 Mar; 29(3):313-21. PubMed ID: 24194373
[TBL] [Abstract][Full Text] [Related]
10. Lysophosphatidic acid downregulates tissue inhibitor of metalloproteinases, which are negatively involved in lysophosphatidic acid-induced cell invasion.
Sengupta S; Kim KS; Berk MP; Oates R; Escobar P; Belinson J; Li W; Lindner DJ; Williams B; Xu Y
Oncogene; 2007 May; 26(20):2894-901. PubMed ID: 17130843
[TBL] [Abstract][Full Text] [Related]
11. Cyclooxygenase-2 functions as a downstream mediator of lysophosphatidic acid to promote aggressive behavior in ovarian carcinoma cells.
Symowicz J; Adley BP; Woo MM; Auersperg N; Hudson LG; Stack MS
Cancer Res; 2005 Mar; 65(6):2234-42. PubMed ID: 15781636
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia enhances lysophosphatidic acid responsiveness in ovarian cancer cells and lysophosphatidic acid induces ovarian tumor metastasis in vivo.
Kim KS; Sengupta S; Berk M; Kwak YG; Escobar PF; Belinson J; Mok SC; Xu Y
Cancer Res; 2006 Aug; 66(16):7983-90. PubMed ID: 16912173
[TBL] [Abstract][Full Text] [Related]
13. LPA3 is a precise therapeutic target and potential biomarker for ovarian cancer.
Zhao P; Yun Q; Li A; Li R; Yan Y; Wang Y; Sun H; Damirin A
Med Oncol; 2022 Jan; 39(2):17. PubMed ID: 34982278
[TBL] [Abstract][Full Text] [Related]
14. Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer.
Lee Z; Swaby RF; Liang Y; Yu S; Liu S; Lu KH; Bast RC; Mills GB; Fang X
Cancer Res; 2006 Mar; 66(5):2740-8. PubMed ID: 16510595
[TBL] [Abstract][Full Text] [Related]
15. Cell type-selective pathways and clinical associations of lysophosphatidic acid biosynthesis and signaling in the ovarian cancer microenvironment.
Reinartz S; Lieber S; Pesek J; Brandt DT; Asafova A; Finkernagel F; Watzer B; Nockher WA; Nist A; Stiewe T; Jansen JM; Wagner U; Konzer A; Graumann J; Grosse R; Worzfeld T; Müller-Brüsselbach S; Müller R
Mol Oncol; 2019 Feb; 13(2):185-201. PubMed ID: 30353652
[TBL] [Abstract][Full Text] [Related]
16. LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2).
So J; Wang FQ; Navari J; Schreher J; Fishman DA
Gynecol Oncol; 2005 Jun; 97(3):870-8. PubMed ID: 15919106
[TBL] [Abstract][Full Text] [Related]
17. Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer.
Fang X; Gaudette D; Furui T; Mao M; Estrella V; Eder A; Pustilnik T; Sasagawa T; Lapushin R; Yu S; Jaffe RB; Wiener JR; Erickson JR; Mills GB
Ann N Y Acad Sci; 2000 Apr; 905():188-208. PubMed ID: 10818454
[TBL] [Abstract][Full Text] [Related]
18. Lysophosphatidic acid activates lipogenic pathways and de novo lipid synthesis in ovarian cancer cells.
Mukherjee A; Wu J; Barbour S; Fang X
J Biol Chem; 2012 Jul; 287(30):24990-5000. PubMed ID: 22665482
[TBL] [Abstract][Full Text] [Related]
19. Activation of AMP-activated protein kinase is essential for lysophosphatidic acid-induced cell migration in ovarian cancer cells.
Kim EK; Park JM; Lim S; Choi JW; Kim HS; Seok H; Seo JK; Oh K; Lee DS; Kim KT; Ryu SH; Suh PG
J Biol Chem; 2011 Jul; 286(27):24036-45. PubMed ID: 21602274
[TBL] [Abstract][Full Text] [Related]
20. [Lysophosphatidic acid as a potential target for treatment and molecular diagnosis of epithelial ovarian cancers].
Tanyi J; Rigó J
Orv Hetil; 2009 Jun; 150(24):1109-18. PubMed ID: 19739275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
